Shoya Ono

Dr. Shoya Ono

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
YKYutaro Kondo
Yutaro Kondo
SSSusumu Suzuki
Susumu Suzuki
SOShoya Ono
Shoya Ono
MGMitsuo Goto
Mitsuo Goto
SMSatoru Miyabe
Satoru Miyabe
TNToru Nagao
Toru Nagao
The expression of programmed death ligand-1 (PD-L1) is controlled by complex mechanisms. The elucidation of the molecular mechanisms of PD-L1 expression is important for the exploration of new insights into PD-1 blockade therapy. Detailed mechanisms of the in situ expression of PD-L1 in tissues of oral squamous cell carcinomas (OSCCs) have not yet been clarified. We examined the mechanisms of PD-L1 expression focusing on the phosphorylation of downstream molecules of epidermal growth factor (EGF) and interferon gamma (IFN-γ) signaling in vitro and in vivo by immunoblotting and multi-fluorescence immunohistochemistry (MF-IHC), respectively. The in vitro experiments demonstrated that PD-L1 expression in OSCC cell lines is upregulated by EGF via the EGF receptor (EGFR)/PI3K/AKT pathway, the EGFR/STAT1 pathway, and the EGFR/MEK/ERK pathway, and by IFN-γ via the JAK2/STAT1 pathway. MF-IHC demonstrated that STAT1 and EGFR phosphorylation was frequently shown in PD-L1-positive cases and STAT1 phosphorylation was correlated with lymphocyte infiltration and EGFR phosphorylation. Moreover, the phosphorylation pattern of the related molecules in PD-L1-positive cells differed among the cases investigated. These findings indicate that PD-L1 expression mechanisms differ depending on the tissue environment and suggest that the examination of the tissue environment and molecular alterations of cancer cells affecting PD-L1 expression make it necessary for each patient to choose the appropriate combination drugs for PD-1 blockade cancer treatment.

Verified
Journal Article
Open access
PDF file
SYShunpei Yamanaka
Shunpei Yamanaka
SSSusumu Suzuki
Susumu Suzuki
HIHideaki Ito
Hideaki Ito
KSKarnan Sivasundaram
Karnan Sivasundaram
IHIchiro Hanamura
Ichiro Hanamura
Yasushi FujimotoYasushi Fujimoto
Yasushi Fujimoto
Patients with advanced/recurrent mucoepidermoid carcinoma (MEC) have a poor prognosis. This study aimed to establish and characterize human mucoepidermoid carcinoma cell lines from the initial surgical specimen and biopsy specimen upon recurrence from the same patient to provide a resource for MEC research. MEC specimens from the initial surgical procedure and biopsy upon recurrence were used to establish cell lines. The established cell lines were cytogenetically characterized using multi-color fluorescence in situ hybridization and detection, and the sequence of the CRTC1-MAML2 chimeric gene was determined. Furthermore, the susceptibility of head and neck mucoepidermoid carcinoma to standard treatment drugs such as cisplatin, 5-fluorouracil, and cetuximab was investigated. We successfully established unique MEC cell lines, AMU-MEC1, from an initial surgical specimen and AMU-MEC1-R1 and AMU-MEC1-R2 from the recurrent biopsy specimen in the same patient. These cell lines exhibited epithelial morphology and developed in vitro-like cobblestones. They shared eight chromosomal abnormalities, including der(19)ins(19;11)(p13;?), which resulted in a chimeric CRTC1-MAML2 gene, indicating the same origin of the cell lines. The susceptibility of all cell lines to cisplatin and 5-fluorouracil was low. Interestingly, EGFR dependency for cell growth decreased in AMU-MEC-R1 and AMU-MEC-R2 but was retained in AMU-MEC1. These cytogenetic and biochemical findings suggest that the established cell lines can be used to investigate the disease progression mechanisms and develop novel therapeutics for MEC.

6 October 2022 in Clinical Case Reports
Verified
Journal Article
Open access
SOShoya Ono
Shoya Ono
MGMitsuo Goto
Mitsuo Goto
SMSatoru Miyabe
Satoru Miyabe
HMHiroyuki Makihara
Hiroyuki Makihara
KKKatsutoshi Kubo
Katsutoshi Kubo
TNToru Nagao
Toru Nagao
Extranodal marginal zone lymphoma of mucosa‐associated lymphoid tissue (MALT) is a low‐grade B‐cell lymphoma. MALT lymphomas involving the sublingual gland are extremely rare. Herein, we report a case of MALT lymphoma of the sublingual gland. Additionally, we discuss challenging diagnostic aspects as well as current treatment strategies.

12 October 2023 in Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology
Verified
Journal Article
Closed access
KNKensuke Naganawa
Kensuke Naganawa
HSHaruki Sato
Haruki Sato
THTaihei Hayakawa
Taihei Hayakawa
SOShoya Ono
Shoya Ono
SNSanako Nakaya
Sanako Nakaya
IOIchiro Oh-Iwa
Ichiro Oh-Iwa

6 November 2024 in Oral Science International
Verified
Journal Article
Closed access
SOShoya Ono
Shoya Ono
RORyosuke Ogikubo
Ryosuke Ogikubo
YTYuki Tange
Yuki Tange
KHKumiko Hatsukawa
Kumiko Hatsukawa
ASAkio Shibata
Akio Shibata
KKKou Kawahara
Kou Kawahara

1 July 2021 in Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology
Verified
Journal Article
Closed access
SOShoya Ono
Shoya Ono
SHShogo Hasegawa
Shogo Hasegawa
SMSatoru Miyabe
Satoru Miyabe
GTGo Takeuchi
Go Takeuchi
YMYoshihisa Morishita
Yoshihisa Morishita
TNToru Nagao
Toru Nagao